Pro Feature
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moExternal Resources
TOLCAPONE by Alvogen is mechanism of action: tolcapone is a selective and reversible inhibitor of catechol- o -methyltransferase (comt). First approved in 2020.
Drug data last refreshed 10h ago
Mechanism of Action: Tolcapone is a selective and reversible inhibitor of catechol- O -methyltransferase (COMT). In mammals, COMT is distributed throughout various organs. The highest activities are in the liver and kidney. COMT also occurs in the heart, lung, smooth and skeletal muscles,…
Worked on TOLCAPONE at Alvogen? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Short-term Effects of TOLCAPONE on Transthyretin Stability in Subjects With Leptomeningeal TTR Amyloidosis (ATTR)
A Study Assessing the Safety and Pharmacokinetic Profile of Modified Release Formulations of Tolcapone
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo